Compare · EXEL vs IKNA
EXEL vs IKNA
Side-by-side comparison of Exelixis Inc. (EXEL) and Ikena Oncology Inc. (IKNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EXEL and IKNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- EXEL carries a market cap of $16.37B.
- EXEL has hit the wire 7 times in the past 4 weeks while IKNA has been quiet.
- EXEL has more recent analyst coverage (25 ratings vs 5 for IKNA).
- Company
- Exelixis Inc.
- Ikena Oncology Inc.
- Price
- -
- -
- Market cap
- $16.37B
- -
- 1M return
- +7.83%
- -
- 1Y return
- +58.19%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- 2021
- News (4w)
- 7
- 0
- Recent ratings
- 25
- 5
Exelixis Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Ikena Oncology Inc.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Latest EXEL
- Kernal Bio Announces Strategic Investment from IFLI and Leadership Appointments
- SEC Form SCHEDULE 13G filed by Exelixis Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Exelixis Inc.
- Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
- SEC Form 10-Q filed by Exelixis Inc.
- SEC Form 8-K filed by Exelixis Inc.
- Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
- Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- Exelixis Inc. filed SEC Form 8-K: Other Events
Latest IKNA
- Ikena Oncology Inc. filed SEC Form 8-K: Leadership Update, Other Events
- SEC Form 4 filed by Chief Executive Officer Yarema Kristin
- Director Orbimed Advisors Llc was granted 83,611 shares (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Ikena Oncology Inc.
- Director Bonita David P converted options into 379 shares and bought $2,499,969 worth of shares (83,611 units at $29.90) (SEC Form 4)
- Director Stampacchia Otello converted options into 379 shares and bought $7,999,924 worth of shares (267,556 units at $29.90) (SEC Form 4)
- Chief Financial Officer Marango Jotin was granted 15,776 shares and covered exercise/tax liability with 4,630 shares (SEC Form 4)
- Principal Accounting Officer Butler Erin was granted 3,051 shares (SEC Form 4)
- SEC Form 3 filed by new insider Butler Erin
- SEC Form 3 filed by new insider Yarema Kristin